Cancer Therapeutics Laboratories

Cancer Therapeutics Laboratories (CTL) is a biotechnology company focused on developing novel immunotherapies for solid tumors using its proprietary Tumor Necrosis Therapy (TNT) platform. Founded by Dr. Alan L. Epstein, the company utilizes monoclonal antibodies to target intracellular antigens, such as DNA-histone complexes, that become accessible in the necrotic regions of tumors. CTL's pipeline includes vasopermeability-enhancing fusion proteins designed to improve the delivery of co-administered chemotherapeutic agents and other biologics. The company has established strategic licensing agreements with partners like ImmunityBio to advance its antibody candidates through clinical trials. Additionally, CTL is exploring applications in veterinary medicine, specifically targeting cancers in canine patients.